Tagged with USA,

USA Janet Lynch Lambert, CEO of the Alliance for Regenerative Medicine (ARM), discusses the association’s aims and membership, the importance of creating a supportive reimbursement environment for regenerative medicine, and the huge and expanding need for education in this critical area. What was the initial inspiration behind setting up the Alliance…

USA In an exclusive interview, Stephen Ubl, President and CEO of the Pharmaceutical Researchers and Manufacturers of America (PhRMA), the association representing the leading innovative biopharmaceutical companies in the USA, discusses the onset of a new “golden era” in medicine. He goes on to discuss pricing issues, engaging in a constructive…

USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…

USA Rolando Pablos, Secretary of State of Texas, discusses Texas’s unique business-friendly environment, the significance of the life sciences sector to the state’s economy (which would be the tenth largest in the world were Texas a country), innovation, and internationalization.   Across the board we are industry agnostic, meaning that whatever…

USA Benjamin Wu of the Maryland Department of Commerce discusses the importance of the life sciences to the state, how Maryland is performing in terms of technology transfer, and its potential as an innovation hub. What is the status of life sciences in Maryland and its particularities? “We host the headquarters…

USA Helen Stimson, president of the Delaware BioScience Association, discusses Delaware’s attractive cost of living, legal system, interconnectivity, as well as the vital role that the life sciences play within the state. Ms. Stimson, after a distinguished career with Agilent Technologies, you became president of the Delaware BioScience Association just a…

USA Speaking exclusively to PharmaBoardroom at the 2017 BIO Convention in San Diego, former FDA Commissioner Andrew von Eschenbach lifts the lid on the ‘FDA Beyond Our Borders’ project that he initiated. Dr. von Eschenbach, you were the FDA Commissioner for three years, from 2006 to 2009. What do you see…

Asia 2016 was a year of great activity for the pharma industry, with economic uncertainties, seismic political shifts in the UK and US, and cost-containment measures in several countries. Consequently, PharmaBoardroom surveyed over 400 of its executive readership over four continents to get a sense of their optimism for the industry in 2017.…

USA While pledging to lower drug prices has proved popular, the Trump administration’s proposed FDA reform has been getting some pharmaceutical executives worried. In a meeting with Big Pharma CEOs at the end of January; US President Donald Trump called for drug prices to be lowered, US production of medicines to…

USA Take our poll on Donald Trump and Pharma at the bottom of the article Speaking at a White House meeting with senior pharmaceutical executives, US President Donald Trump told drug companies to lower their “astronomical” prices. He pledged to curb regulations and lower tax rates to allow companies to do so,…

Pharma The Executive Director of AmCham Singapore, former US Ambassador Judith Fergin, highlights why American companies are the largest source of FDI in the country and how Singapore’s enterprise-friendly environment has made it a hotbed for international investor interest. Can you please provide an overview of the chamber’s presence within Singapore…

Pharma Martin Naville, CEO of the Swiss-American Chamber of Commerce, discusses Swiss exports to the US, global competitiveness and innovation rankings, and why the Swiss-US relationship will only continue to grow stronger in the coming years. In 2015, the US was the most important destination for Swiss direct investment abroad, amounting…